AbbVie Inc. (NYSE: ABBV) is trading lower on Tuesday, December 16, 2025, after a strong run earlier in the quarter and a Monday close that kept the stock near the upper end of its 52‑week range. As of 17:54 UTC on Dec. 16, ABBV was at $222.44, down $5.01 (-2.20%) on the session, with an intraday range of $222.44 to $228.00.
Today’s AbbVie coverage is being driven less by a single blockbuster headline and more by the familiar mix of Wall Street recalibration and pipeline expectations: Bank of America trimmed its price target, while fresh pipeline-focused analysis reiterated the thesis that AbbVie’s next wave of launches and label expansions—especially around Rinvoq—could power the company’s post‑Humira growth story through 2026 and beyond. [1]
Below is a detailed, publication-ready snapshot of what’s moving ABBV today, what analysts are forecasting, and which catalysts long-term investors are watching most closely.
AbbVie stock price today: ABBV slips as the market reassesses valuation
AbbVie shares are pulling back about 2% in Tuesday trading—an important detail because the stock has been priced more like a “premium defensive” than a typical big pharma name in recent months. While AbbVie’s business mix (large immunology franchise, cash flow, dividend) often attracts risk‑aware investors, valuation sensitivity tends to rise late in the year as portfolio managers lock in gains and rotate exposure.
Real-time pricing on Tuesday showed ABBV near $222–$223 around midday in the U.S. session, consistent with the broader down move captured in market feeds. [2]
Today’s top analyst headline: BofA lowers AbbVie price target to $233
A key piece of stock-specific news on Dec. 16: Bank of America lowered its AbbVie price target to $233 from $248 and maintained a Neutral rating. [3]
BofA’s framing matters for how the buy-side interprets ABBV right now:
- The firm described a “clean setup” for growth relative to peers, but argued the upside is balanced by a premium multiple and limited late-stage pipeline catalysts (in their view).
- BofA also noted it is shifting its valuation basis to FY27 estimates, effectively pushing the discussion from near-term execution into what AbbVie can deliver deeper into the decade. [4]
In plain English: BofA isn’t calling the story broken—it’s calling the stock less mispriced at current levels, which can be enough to pressure shares when sentiment is already crowded.
AbbVie stock forecast: what Wall Street expects now (price targets and consensus)
Despite today’s BofA trim, consensus still leans positive—but the spread between bullish and cautious targets remains wide.
Consensus targets (multiple trackers)
One widely-followed consensus summary shows:
- Consensus rating: “Buy”
- Average 12‑month price target:$242.28
- Range:$190 (low) to $289 (high) [5]
A separate tracker built from a larger set of analyst notes pegs AbbVie’s consensus target around the mid‑$240s, with a “Moderate Buy” style consensus. [6]
Recent notable analyst actions (context going into year-end)
Recent changes in December (prior to today) show how divided the Street is on valuation vs. durability:
- Morgan Stanley maintained a Buy rating and raised its target (listed as $261 → $269). [7]
- HSBC upgraded from Hold → Strong Buy and raised its target (listed as $225 → $265). [8]
- BofA’s $233 target (Neutral) now sits below the pack, reflecting the “premium multiple” concern. [9]
How to read this for Dec. 16: the bull case is still alive in published forecasts, but AbbVie is trading in a zone where “good company” doesn’t automatically mean “automatic multiple expansion.”
Pipeline and launch outlook: why Rinvoq, tavapadon and PVEK are central to the ABBV narrative
The most substantive AbbVie-specific analysis published today focused on pipeline launch sequencing and the next set of catalysts investors may care about.
A Dec. 16 pipeline note highlighted three core pillars:
1) Rinvoq label expansions (the “second act” growth lever)
The analysis emphasized AbbVie’s push to expand Rinvoq into additional indications—systemic lupus erythematosus (SLE), hidradenitis suppurativa (HS), vitiligo, alopecia areata (AA), and Takayasu arteritis—and said AbbVie believes these expansions could add roughly $2 billion to Rinvoq peak-year sales. [10]
Two timing details are particularly market-relevant:
- AbbVie expects to file a regulatory submission for alopecia areata before the end of 2025. [11]
- Data readouts from HS and SLE studies are anticipated in 2026. [12]
2) Tavapadon (Parkinson’s disease)
On neuroscience, AbbVie’s tavapadon is framed as a potential launch with commercial weight. The Dec. 16 analysis said AbbVie has already submitted a regulatory filing seeking approval for tavapadon as a once-daily oral Parkinson’s therapy, supported by three late-stage studies. [13]
The same note positioned this as potentially AbbVie’s second FDA clearance in Parkinson’s disease after Vyalev, with early launch uptake described as encouraging. [14]
3) Pivekimab sunirine (PVEK) and oncology expansion
In oncology, the Dec. 16 analysis said PVEK (pivekimab sunirine), an antibody-drug conjugate (ADC), is under FDA review for BPDCN, a rare aggressive blood cancer, and could become another ADC entry in AbbVie’s portfolio. [15]
AbbVie previously announced it submitted a BLA to the FDA for PVEK, providing further official-company context to the “under review” framing. [16]
The same pipeline note also flagged additional late-stage oncology programs, including Temab‑A (metastatic colorectal cancer) and etentamig (relapsed/refractory multiple myeloma). [17]
AbbVie’s R&D scale: the “engine” behind the pipeline thesis
One reason the pipeline discussion carries unusual weight for ABBV is the company’s sheer R&D and program breadth.
AbbVie’s published pipeline overview states (as last updated Sept. 8, 2025):
- ~90 compounds/devices/indications in development (including collaborations/licenses)
- $10.8B R&D investment in 2024
- ~60 programs in mid- and late-stage development [18]
For investors, that breadth can work both ways:
- Positive: multiple “shots on goal” to refresh the portfolio.
- Risk: capital allocation and execution discipline become more important as the pipeline expands across modalities (small molecules, biologics, ADCs, etc.).
The M&A layer: AbbVie keeps buying future options
AbbVie’s growth narrative is also being shaped by dealmaking.
A Dec. 16 pipeline analysis stated AbbVie has executed more than 30 M&A transactions since the beginning of 2024, including deals that helped bring key assets into the portfolio. [19]
On the neuroscience side, AbbVie announced it completed the acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin in October 2025, following an August 2025 definitive agreement. [20]
This matters for the stock because AbbVie is actively building a post-Humira portfolio, and investors tend to reward clarity on what replaces legacy cash flows.
Fundamentals check: AbbVie’s latest reported quarter shows Skyrizi and Rinvoq doing heavy lifting
The biggest fundamental anchor for ABBV (still) is the ability of Skyrizi and Rinvoq to offset the Humira decline.
In its Q3 2025 report (released Oct. 31, 2025), AbbVie said:
- Worldwide net revenues: $15.776B, up 9.1% reported
- Immunology portfolio: $7.885B, up 11.9%
- Skyrizi:$4.708B, up 46.8%
- Rinvoq:$2.184B, up 35.3%
- Humira:$993M, down 55.4% [21]
AbbVie also raised full‑year guidance:
- 2025 adjusted diluted EPS raised to $10.61–$10.65 [22]
And it announced a shareholder-return headline that remains relevant heading into 2026:
- Quarterly dividend increased to $1.73, beginning with the dividend payable in February 2026. [23]
Options-market analysis published today: what derivatives pricing implies for ABBV
Another Dec. 16 item that traders are watching: an options-flow based analysis that tries to infer market-maker expectations.
A Barchart analysis described an expected trading range over roughly 10 weeks and discussed a bull call spread idea (buy the $230 call / sell the $240 call) expiring Feb. 20, 2026, while cautioning that the pricing implied market makers did not view a move much past $240 as especially likely within that window. [24]
Important caveat for readers: options-flow articles are not forecasts in the way analyst models are—they’re snapshots of positioning and implied probabilities at a moment in time.
Institutional positioning headlines today: what 13F-driven reports are saying
Several “today” headlines around ABBV are essentially institutional-holdings stories tied to 13F filings and end-of-quarter positioning:
- One report said GAMMA Investing LLC increased its AbbVie stake in Q3 and recapped AbbVie’s quarter and dividend hike. [25]
- Another highlighted Shorepoint Capital Partners initiating a position during Q3, again repeating key earnings and dividend details. [26]
- A third noted Park National Corp OH reduced its stake during Q3. [27]
These are useful for sentiment color, but readers should remember: 13F filings are backward-looking and don’t necessarily explain today’s intraday move.
Key risks investors are weighing on Dec. 16
ABBV’s investment case is widely followed, which means the stock can react sharply when any of these pressure points rise:
- Valuation risk: As highlighted by BofA, AbbVie can be viewed as fully valued when the market’s discount rate rises or when “defensive” positioning gets crowded. [28]
- Humira erosion: Still a headwind, even as Skyrizi and Rinvoq grow. [29]
- Pipeline timing and regulatory risk: The bull case assumes smooth sequencing of submissions, readouts, and approvals across multiple programs. [30]
- Competition in immunology: Large peers continue to fight for IBD and related immunology markets, and competitive dynamics can shift quickly with new data and labels. [31]
- Aesthetics softness: AbbVie’s aesthetics portfolio declined in Q3 (per company reporting), and macro sensitivity remains a watch item into 2026. [32]
What to watch next: ABBV catalysts into early 2026
Here are the near-term checkpoints most likely to shape ABBV headlines over the next several weeks:
- Rinvoq (AA) regulatory submission expected before year-end 2025 (per pipeline analysis). [33]
- 2026 clinical readouts (HS and SLE studies) that could extend the Rinvoq growth runway. [34]
- Tavapadon regulatory review progress (Parkinson’s) as investors look for clarity on timing and commercial positioning. [35]
- PVEK FDA review developments for BPDCN (and broader ADC strategy). [36]
- Next earnings date (estimated): market calendars currently estimate AbbVie’s next earnings report around Jan. 30, 2026, though dates can change until the company confirms. [37]
Bottom line for Dec. 16, 2025
AbbVie stock is lower today, and the clearest stock-specific catalyst in today’s newsflow is Bank of America’s price-target cut—a reminder that ABBV’s “quality + dividend” profile doesn’t make it immune to valuation-driven pullbacks. [38]
At the same time, the constructive long-term story remains recognizable: Skyrizi and Rinvoq are growing fast, AbbVie is investing heavily in R&D, and the next set of potential launches (Rinvoq expansions, tavapadon, PVEK) continue to frame the company’s post‑Humira growth pathway. [39]
References
1. www.tipranks.com, 2. stockanalysis.com, 3. www.tipranks.com, 4. www.tipranks.com, 5. stockanalysis.com, 6. www.marketbeat.com, 7. stockanalysis.com, 8. stockanalysis.com, 9. www.tipranks.com, 10. finviz.com, 11. finviz.com, 12. finviz.com, 13. finviz.com, 14. finviz.com, 15. finviz.com, 16. news.abbvie.com, 17. finviz.com, 18. www.abbvie.com, 19. finviz.com, 20. news.abbvie.com, 21. news.abbvie.com, 22. news.abbvie.com, 23. news.abbvie.com, 24. www.barchart.com, 25. www.marketbeat.com, 26. www.marketbeat.com, 27. www.marketbeat.com, 28. www.tipranks.com, 29. news.abbvie.com, 30. finviz.com, 31. finviz.com, 32. news.abbvie.com, 33. finviz.com, 34. finviz.com, 35. finviz.com, 36. finviz.com, 37. www.nasdaq.com, 38. www.tipranks.com, 39. news.abbvie.com
